Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Policy / Regulatory

BIO Survey Highlights Extensive Dependence on Chinese CDMOs in Life Sciences

Fineline Cube May 11, 2024

The Biotechnology Innovation Organization (BIO), a US industry trade group, has completed a survey among...

Company Drug

Yunnan Baiyao’s Radiopharmaceutical INR101 Advances to Clinical Trial Stage with NMPA Approval

Fineline Cube May 11, 2024

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...

Company Drug

Eisai’s Fycompa Gains New Indication for Generalized Tonic-Clonic Seizures in China

Fineline Cube May 11, 2024

Eisai Co Ltd (TYO: 4523), a Japanese pharmaceutical company, has announced that its antiepilepsy drug...

Company Deals

Ribobay Pharma and General Biol to Commence GMP-Grade Oligonucleotide Manufacturing Services

Fineline Cube May 11, 2024

Shanghai-based contract research, development, and manufacturing organization (CRDMO) Ribobay Pharma has announced plans to commence...

Company Policy / Regulatory

BioSecure Act Advances in US, Aiming to Curb Ties with Chinese Bioscience Firms

Fineline Cube May 11, 2024

US legislators are working expeditiously to finalize the BioSecure Act, legislation that, if enacted, would...

Company Drug

Jacobio Pharma’s KRAS G12C Inhibitor Gains NMPA Approval for Phase III CRC Study

Fineline Cube May 11, 2024

Jacobio Pharma (HKG: 1167), a biopharmaceutical company based in China, has announced that it has...

Company Deals

Tianjin Lisheng Pharmaceutical Co., Ltd. to Sell Stake in Mitsubishi Tanabe’s China Subsidiary

Fineline Cube May 11, 2024

Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to...

Company Drug

Qilu Pharmaceutical Achieves First Approval for Generic Bendamustine in China

Fineline Cube May 11, 2024

The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic bendamustine,...

Company Deals

Macera Therapeutics and Innorna Co., Ltd Collaborate on CAR-M mRNA-LNP Technology

Fineline Cube May 11, 2024

Macera Therapeutics, a company based in Nanjing specializing in the development of macrophage immunotherapies, has...

Company Deals

Vazyme Biotech and SPH KDL Health Join Forces to Promote Alzheimer’s Blood Tests

Fineline Cube May 11, 2024

Vazyme Biotech Co., Ltd (SHA: 688105), a prominent biotech company based in China, has entered...

Company Medical Device

Jiangsu BioPerfectus’ Dengue Detection Kit Gains NMPA Approval for Commercialization

Fineline Cube May 11, 2024

Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading in vitro diagnostic (IVD) product manufacturer...

Company Deals

DSciLab, mRNA Pharma Startup, Bags RMB 100 Million in Angel Financing Led by Fosun Health

Fineline Cube May 11, 2024

DSciLab Co., Ltd, a China-based mRNA pharmaceutical company nurtured by Fosun Health Capital, has announced...

Company Deals

Novo Nordisk Partners with Flagship Pioneering for Development of Novel Obesity Treatments

Fineline Cube May 11, 2024

Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced a partnership with life sciences venture...

Company

Viatris Q1 2024 Results Show Slight Dip in Base Business Brands Amid Overall Stabilization

Fineline Cube May 11, 2024

US pharmaceutical company Viatris (NASDAQ: VTRS) has reported its financial results for the first quarter...

Company Deals

Sanofi Secures Novavax Vaccine Tech in a Deal Valued at Up to USD 1.2 Billion

Fineline Cube May 11, 2024

France’s Sanofi (NASDAQ: SNY) has announced a strategic partnership with protein-based vaccines specialist Novavax (NASDAQ:...

Policy / Regulatory

China Unveils Sweeping 2024 Legislative Plan with Healthcare and Pharma at Forefront

Fineline Cube May 11, 2024

The State Council of China has released its annual legislative work plan for 2024, outlining...

Company Drug

MSD’s Keytruda Adjuvant Treatment for High-Risk Endometrial Cancer Fails to Meet Primary Endpoint

Fineline Cube May 10, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...

Company

Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip

Fineline Cube May 10, 2024

Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been...

Company Drug

WestGene Biopharma’s Groundbreaking mRNA Vaccine for EB Virus Tumors Gets FDA Green Light

Fineline Cube May 10, 2024

WestGene Biopharma Co., Ltd., a biopharmaceutical company based in Chengdu, has announced that its drug...

Company Drug

RJK Biopharma’s RJK002 Earns Tacit Approval for Amyotrophic Lateral Sclerosis Clinical Trial

Fineline Cube May 10, 2024

Shanghai-based RJK Biopharma Ltd. has announced that its Category 1 drug RJK002 has received tacit...

Posts pagination

1 … 408 409 410 … 711

Recent updates

  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
  • Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201
  • InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.